Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGEN 
Compugen (CGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.25
1 Year Target Price $6.25
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 210.59% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 129.08M USD | Price to earnings Ratio - | 1Y Target Price 6.25 |
Price to earnings Ratio - | 1Y Target Price 6.25 | ||
Volume (30-day avg) 4 | Beta 2.59 | 52 Weeks Range 1.13 - 2.66 | Updated Date 09/17/2025 |
52 Weeks Range 1.13 - 2.66 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -87.45% | Operating Margin (TTM) -670.57% |
Management Effectiveness
Return on Assets (TTM) -11.43% | Return on Equity (TTM) -35.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32052424 | Price to Sales(TTM) 5.83 |
Enterprise Value 32052424 | Price to Sales(TTM) 5.83 | ||
Enterprise Value to Revenue 1.45 | Enterprise Value to EBITDA -19.16 | Shares Outstanding 93535400 | Shares Floating 91623494 |
Shares Outstanding 93535400 | Shares Floating 91623494 | ||
Percent Insiders 2.03 | Percent Institutions 16.56 |
Upturn AI SWOT
Compugen
Company Overview
History and Background
Compugen was founded in 1993. Initially focused on computational genomics, it has evolved into a clinical-stage drug discovery and development company targeting cancer and immunology through novel drug targets.
Core Business Areas
- Immuno-Oncology: Discovery and development of novel therapeutic candidates targeting cancer immunotherapy, focusing on first-in-class therapies.
- Computational Drug Discovery: Utilizing computational biology platforms to identify novel drug targets and develop therapeutic antibodies and other biologics.
Leadership and Structure
Anat Cohen-Dayag, Ph.D. is the President and CEO. The company operates with a structure typical of biotech firms, comprising research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- COM701: A first-in-class anti-PVRIG antibody in Phase 2 clinical trials for solid tumors in combination with Opdivo (nivolumab). Market share is not applicable as it is in clinical development. Competitors include companies developing similar checkpoint inhibitors.
- BAY 1905254 (formerly COM902): An anti-TIGIT antibody partnered with Bayer, in Phase 1 development, Market share is not applicable as it is in clinical development. Competitors include Roche (tiragolumab) and Gilead (domvanalimab).
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by the success of checkpoint inhibitors and the increasing demand for novel cancer therapies.
Positioning
Compugen is positioned as an innovator in cancer immunotherapy, focusing on novel target discovery through its computational platform. Competitive advantages include its unique target identification platform and proprietary antibody pipeline.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of USD in the coming years. Compugen aims to capture a portion of this market through successful clinical development and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary computational drug discovery platform
- Novel drug targets
- Strategic partnerships with established pharmaceutical companies (e.g., Bayer)
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on partnerships for development and commercialization
Opportunities
- Expansion of pipeline through novel target discovery
- Potential for breakthrough therapies in cancer
- Out-licensing or partnering opportunities for existing and future programs
- Growing demand for innovative immuno-oncology therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in the immuno-oncology landscape
Competitors and Market Share
Key Competitors
- BMY
- MRK
- GILD
- ROCHE (ROG.SW)
Competitive Landscape
Compugen competes with larger pharmaceutical companies in the immuno-oncology space. Its advantages lie in its novel target discovery platform, but disadvantages stem from limited financial resources and clinical trial risks.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancements in its clinical programs and collaborations.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization success. Analyst projections vary based on the perceived value of its pipeline.
Recent Initiatives: Focus on advancing COM701 and BAY 1905254 through clinical trials. Expanding partnerships to accelerate drug development and commercialization.
Summary
Compugen is a clinical-stage biotech company focused on novel immuno-oncology therapies. Its strengths include a unique target discovery platform and strategic partnerships, but weaknesses lie in its limited financial resources and dependence on clinical trial success. Opportunities arise from expanding its pipeline and capitalizing on the growing immuno-oncology market, while threats include clinical trial failures and competition from larger pharmaceutical firms. The company needs to focus on strong clinical data to further prove its unique target discovery platform.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compugen
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2000-08-11 | CEO, President & Director Dr. Anat Cohen-Dayag Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://cgen.com |
Full time employees 74 | Website https://cgen.com | ||
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.